Jim Simons Freeline Therapeutics Holdings PLC Transaction History

Renaissance Technologies LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$0.42 - $0.63 $14,368 - $21,552	34,210 Added 17.42%	230,600 $105,000
Q4 2022 Feb 13, 2023	SELL	$0.46 - $0.73 $8,100 - $12,855	-17,610 Reduced 8.23%	196,390 $93,000
Q3 2022 Nov 14, 2022	SELL	$0.69 - $1.1 $35,343 - $56,345	-51,223 Reduced 19.31%	214,000 $150,000
Q2 2022 Aug 12, 2022	SELL	$0.69 - $1.12 $125,020 - $202,931	-181,189 Reduced 40.59%	265,223 $231,000
Q1 2022 May 13, 2022	BUY	$0.92 - $2.03 $217,407 - $479,713	236,312 Added 112.48%	446,412 $500,000
Q4 2021 Feb 11, 2022	BUY	$1.97 - $3.45 $30,732 - $53,820	15,600 Added 8.02%	210,100 $416,000
Q3 2021 Nov 12, 2021	BUY	$3.04 - $8.9 $591,280 - $1.73 Million	194,500 New	194,500 $663,000

30.1K

Ticker FRLN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,972,300
Description
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in P...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.